Search Results - "Hart, M Ragan"

Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies by Robinson, Jill O., Wynn, Julia, Biesecker, Barbara, Biesecker, Leslie G., Bernhardt, Barbara, Brothers, Kyle B., Chung, Wendy K., Christensen, Kurt D., Green, Robert C., McGuire, Amy L., Hart, M. Ragan, Griesemer, Ida, Patrick, Donald L., Rini, Christine, Veenstra, David, Cronin, Angel M., Gray, Stacy W.

“…Purpose As exome and genome sequencing (ES/GS) enters the clinic, there is an urgent need to understand the psychological effects of test result disclosure…”
Get full text

The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation by Li, Meng, Bennette, Caroline S., Amendola, Laura M., Ragan Hart, M., Heagerty, Patrick, Comstock, Bryan, Tarczy‐Hornoch, Peter, Fullerton, Stephanie M., Regier, Dean A., Burke, Wylie, Trinidad, Susan B., Jarvik, Gail P., Veenstra, David L., Patrick, Donald L.

“…The purpose of this study was to develop a brief instrument, the Feelings About genomiC Testing Results (FACToR), to measure the psychosocial impact of…”
Get full text

Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests by Amendola, Laura M., Hart, M. Ragan, Bennett, Robin L., Horike‐Pyne, Martha, Dorschner, Michael, Shirts, Brian, Jarvik, Gail P.

“…In this work, we explore the results of germline cancer genetic tests in individuals whose insurance would not cover this testing. We enrolled 31 patients with…”
Get full text

Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study by Hart, M. Ragan, Biesecker, Barbara B., Blout, Carrie L., Christensen, Kurt D., Amendola, Laura M., Bergstrom, Katie L., Biswas, Sawona, Bowling, Kevin M., Brothers, Kyle B., Conlin, Laura K., Cooper, Greg M., Dulik, Matthew C., East, Kelly M., Everett, Jessica N., Finnila, Candice R., Ghazani, Arezou A., Gilmore, Marian J., Goddard, Katrina A. B, Jarvik, Gail P., Johnston, Jennifer J., Kauffman, Tia L., Kelley, Whitley V., Krier, Joel B., Lewis, Katie L., McGuire, Amy L., McMullen, Carmit, Ou, Jeffrey, Plon, Sharon E., Rehm, Heidi L., Richards, C. Sue, Romasko, Edward J., Miren Sagardia, Ane, Spinner, Nancy B., Thompson, Michelle L., Turbitt, Erin, Vassy, Jason L., Wilfond, Benjamin S., Veenstra, David L., Berg, Jonathan S., Green, Robert C., Biesecker, Leslie G., Hindorff, Lucia A.

“…Purpose Clinical sequencing emerging in health care may result in secondary findings (SFs). Methods Seventy-four of 6240 (1.2%) participants who underwent…”
Get full text

Consideration for Employer-Based and Geographic Attributes Included in Value Assessment Methods of Next-Generation Sequencing Tests by Hart, M Ragan, Spencer, Scott J

“…There is a need for formal cost-effectiveness evidence to better model the real-world payer decision context in which general economic models are currently…”
Get full text

The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation by Li, Meng, Bennette, Caroline S, Amendola, Laura M, Ragan Hart, M, Heagerty, Patrick, Comstock, Bryan, Tarczy-Hornoch, Peter, Fullerton, Stephanie M, Regier, Dean A, Burke, Wylie, Trinidad, Susan B, Jarvik, Gail P, Veenstra, David L, Patrick, Donald L

“…The purpose of this study was to develop a brief instrument, the Feelings About genomiC Testing Results (FACToR), to measure the psychosocial impact of…”
Get full text

Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention by Hart, M. Ragan, Garrison, Louis P., Doyle, Debra L., Jarvik, Gail P., Watkins, John, Devine, Beth

“…For patients undergoing percutaneous coronary intervention, gene-drug associations exist relevant to first-line treatment options–antiplatelet agent,…”
Get full text

Correction: Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study by Hart, M. Ragan, Biesecker, Barbara B., Blout, Carrie L., Christensen, Kurt D., Amendola, Laura M., Bergstrom, Katie L., Biswas, Sawona, Bowling, Kevin M., Brothers, Kyle B., Conlin, Laura K., Cooper, Greg M., Dulik, Matthew C., East, Kelly M., Everett, Jessica N., Finnila, Candice R., Ghazani, Arezou A., Gilmore, Marian J., Goddard, Katrina A. B., Jarvik, Gail P., Johnston, Jennifer J., Kauffman, Tia L., Kelley, Whitley V., Krier, Joel B., Lewis, Katie L., McGuire, Amy L., McMullen, Carmit, Ou, Jeffrey, Plon, Sharon E., Rehm, Heidi L., Richards, C. Sue, Romasko, Edward J., Sagardia, Ane Miren, Spinner, Nancy B., Thompson, Michelle L., Turbitt, Erin, Vassy, Jason L., Wilfond, Benjamin S., Veenstra, David L., Berg, Jonathan S., Green, Robert C., Biesecker, Leslie G., Hindorff, Lucia A.

“…The originally published version of this Article contained errors in Fig. 2. The numbers below the black arrowheads were incorrect; please see incorrect Figure…”
Get full text

Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study by Hart, M. Ragan, Biesecker, Barbara B., Blout, Carrie L., Christensen, Kurt D., Amendola, Laura M., Bergstrom, Katie L., Biswas, Sawona, Bowling, Kevin M., Brothers, Kyle B., Conlin, Laura K., Cooper, Greg M., Dulik, Matthew C., East, Kelly M., Everett, Jessica N., Finnila, Candice R., Ghazani, Arezou A., Gilmore, Marian J., Goddard, Katrina A. B, Jarvik, Gail P., Johnston, Jennifer J., Kauffman, Tia L., Kelley, Whitley V., Krier, Joel B., Lewis, Katie L., McGuire, Amy L., McMullen, Carmit, Ou, Jeffrey, Plon, Sharon E., Rehm, Heidi L., Richards, C. Sue, Romasko, Edward J., Miren Sagardia, Ane, Spinner, Nancy B., Thompson, Michelle L., Turbitt, Erin, Vassy, Jason L., Wilfond, Benjamin S., Veenstra, David L., Berg, Jonathan S., Green, Robert C., Biesecker, Leslie G., Hindorff, Lucia A.

Get full text

Exploring Strategies to Optimize the Value of Pharmacogenomic Testing by Hart, M Ragan

“…The emergence and continual advancement of genomic technologies offer numerous areas that warrant a critical appraisal for integrating new health care services…”
Get full text

Secondary findings from clinical genomic sequencing: Prevalence, patient perspectives, family history assessment, and healthcare costs from a multi-site study by Hart, M. Ragan, Biesecker, Barbara B., Blout, Carrie L., Christensen, Kurt D., Amendola, Laura M., Bergstrom, Katie L., Biswas, Sawona, Bowling, Kevin M., Brothers, Kyle B., Conlin, Laura K., Cooper, Greg M., Dulik, Matthew C., East, Kelly M., Everett, Jessica N., Finnila, Candice R., Ghazani, Arezou A., Gilmore, Marian J., Goddard, Katrina AB, Jarvik, Gail P., Johnston, Jennifer J., Kauffman, Tia L., Kelley, Whitley V., Krier, Joel B., Lewis, Katie L., McGuire, Amy L., Mullen, Carmit Mc, Ou, Jeffrey, Plon, Sharon E., Rehm, Heidi L., Richards, C. Sue, Romasko, Edward J., Sagardia, Ane Miren, Spinner, Nancy B., Thompson, Michelle L., Turbitt, Erin, Vassy, Jason L., Wilfond, Benjamin S., Veenstra, David L., Berg, Jonathan S., Green, Robert C., Biesecker, Leslie G., Hindorff, Lucia A.

Get full text

The Effect of Gene-Obesity and Gene-Care Setting Interactions on Risk of Major Bleeding Events in Warfarin Users by Hart, M Ragan

“…A commonly prescribed anticoagulant, Warfarin (Coumadin®), reduces thromboembolic (blood clotting) event rates in patients with atrial fibrillation, stroke,…”
Get full text

The Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting by Hart, Ragan, MS, Veenstra, David L., PharmD, PhD, Boudreau, Denise M., PhD, Roth, Joshua A., MHA, PhD

“…Abstract Purpose Several studies have demonstrated an association between body mass index (BMI) and warfarin therapeutic dose, but none evaluated the…”
Get full text